📈 69% of S&P 500 stocks beating the index - a historic record! Pick the best ones with AI.See top stocks

UPDATE 1-Canadian marijuana firm Canopy 3rd-qtr rev jumps, but misses view

Published 2018-02-14, 08:39 a/m
© Reuters.  UPDATE 1-Canadian marijuana firm Canopy 3rd-qtr rev jumps, but misses view
WEED
-
APHA
-
HEXO
-
ACB
-
EAGR
-

By Nichola Saminather

TORONTO, Feb 14 (Reuters) - Canopy Growth Corp WEED.TO, Canada's biggest marijuana producer, said on Wednesday its third-quarter revenue doubled and profit rose, even as analysts expected a loss.

Net profit rose to C$11 million from C$3 million a year earlier. Analysts, on average, looked for a loss of $7.1 million. The earnings included a one-time gain of C$8.8 million from the sale of Canopy's Agripharm business.

Earnings per share fell to 1 Canadian cent from 3 Canadian cents as the number of outstanding shares rose. Excluding the one-time gain, the company had a loss of 2 Canadian cents, compared with expectations for a loss of 5 Canadian cents, according to Thomson Reuters I/B/E/S.

Quarterly revenue jumped 123 percent to C$21.7 million ($17.26 million), but missed the average analyst estimate of C$24.2 million.

Smiths Falls, Ontario-based company Canopy is at the center of the investor frenzy surrounding Canadian marijuana companies ahead of the national legalization of recreational use this year.

Its shares closed at C$26.72 on Tuesday, about three times its price just six months ago.

The company and rivals Aurora Cannabis ACB.TO , Aphria APH.TO , MedReleaf LEAF.TO , Hydropothecary Corp THCX.V and Tilray, owned by private equity firm Privateer Holdings, all said Wednesday they had signed supply agreements with the province of Quebec. already has multiyear commitments to supply Prince Edward Island, Newfoundland & Labrador and New Brunswick.

Canopy posted record German sales of C$1 million in the quarter, all from domestic Canadian production.

In addition to recreational use in Canada, companies like Canopy are ramping up supply to export to countries including Germany, Peru and Australia, which have legalized medical cannabis, with more nations expected to follow.

The company recorded patient growth of 138 percent in the quarter, and sales rose 87 percent to a record 2,330 kilograms. The average sale price climbed 13 percent to C$8.30 per gram.

It had cash and cash equivalents of C$237.7 million at the end of the quarter.

($1 = 1.2576 Canadian dollars)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.